2026 ICD-10-CM Diagnosis Code T44.1X6AUnderdosing of other parasympathomimetics [cholinergics], initial encounter
T44.1X6A is a billable ICD-10-CM diagnosis code for underdosing of other parasympathomimetics [cholinergics], initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The code is not accepted as a principal diagnosis by the Medicare Code Editor. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Underdosing of drugs and medicaments, initial encounter.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T44.1X6A.
Coding GuidelinesGuidance
Underdosing refers to taking less of a medication than is prescribed by a provider or a manufacturer's instruction. Codes for underdosing should never be assigned as principal or first-listed codes. If a patient has a relapse or exacerbation of the medical condition for which the drug is prescribed because of the reduction in dose, then the medical condition itself should be coded.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system (T44). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Acetylcholine
a neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system.Acetylcholine Release Inhibitors
compounds that block release of the neurotransmitter acetylcholine.Acetylcholinesterase
an enzyme that catalyzes the hydrolysis of acetylcholine to choline and acetate. in the cns, this enzyme plays a role in the function of peripheral neuromuscular junctions. ec 3.1.1.7.Cholinergic Agents
any drug used for its actions on cholinergic systems. included here are agonists and antagonists, drugs that affect the life cycle of acetylcholine, and drugs that affect the survival of cholinergic neurons. the term cholinergic agents is sometimes still used in the narrower sense of muscarinic agonists, although most modern texts discourage that usage.Cholinergic Agonists
drugs that bind to and activate cholinergic receptors.Cholinergic Antagonists
drugs that bind to but do not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.Cholinesterase Inhibitors
drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.Receptors, Cholinergic
cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology.Receptors, Muscarinic
one of the two major classes of cholinergic receptors. muscarinic receptors were originally defined by their preference for muscarine over nicotine. there are several subtypes (usually m1, m2, m3....) that are characterized by their cellular actions, pharmacology, and molecular biology.Receptors, Nicotinic
one of the two major classes of cholinergic receptors. nicotinic receptors were originally distinguished by their preference for nicotine over muscarine. they are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors.Vesicular Acetylcholine Transport Proteins
vesicular amine transporter proteins that transport the neurotransmitter acetylcholine into small secretory vesicles. proteins of this family contain 12 transmembrane domains and exchange vesicular protons for cytoplasmic acetylcholine.Arecoline
an alkaloid obtained from the betel nut (areca catechu), fruit of a palm tree. it is an agonist at both muscarinic and nicotinic acetylcholine receptors. it is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. it has been used as a euphoriant in the pacific islands.Bethanechol
a slowly hydrolyzing muscarinic agonist with no nicotinic effects. bethanechol is generally used to increase smooth muscle tone, as in the gi tract following abdominal surgery or in urinary retention in the absence of obstruction. it may cause hypotension, heart rate changes, and bronchial spasm.Bethanechol Compounds
quaternary ammonium compounds that include bethanechol.Carbachol
a slowly hydrolyzed cholinergic agonist that acts at both muscarinic receptors and nicotinic receptors.Pilocarpine
a slowly hydrolyzed muscarinic agonist with no nicotinic effects. pilocarpine is used as a miotic and in the treatment of glaucoma.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
| Substance | Accidental | Self-harm | Assault | Undetermined | Adverse Effect | Underdosing |
|---|---|---|---|---|---|---|
| Aceclidine | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Acetylcholine | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Acetylcholine::chloride | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Acetylcholine::derivative | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Arecoline | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Benzpyrinium bromide | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Bethanechol | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Bethanechol::chloride | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Carbachol | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Carbamylcholine chloride | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Cholinergic (drug) NEC | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Cholinergic (drug) NEC::muscle tone enhancer | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Cholinergic (drug) NEC::organophosphorus | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Cholinergic (drug) NEC::organophosphorus::insecticide | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Cholinergic (drug) NEC::organophosphorus::nerve gas | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Cholinergic (drug) NEC::trimethyl ammonium propanediol | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Methacholine | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Parasympathomimetic drug NEC | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Pilocarpine | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
| Pilocarpus (jaborandi) extract | T44.1X1 | T44.1X2 | T44.1X3 | T44.1X4 | T44.1X5 | T44.1X6 |
Patient EducationClinical
Medication Errors
Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T44.1X6A to ICD-9-CMHistory
Code HistoryHistory
Questions About T44.1X6AOverview
Is T44.1X6A (Underdosing of other parasympathomimetics [cholinergics]) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report underdosing of other parasympathomimetics [cholinergics], initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character A in T44.1X6A mean?
The final character A marks the initial encounter: use it while the patient is receiving active treatment for underdosing of other parasympathomimetics [cholinergics], such as an emergency visit or first evaluation.
Can T44.1X6A be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because underdosing of other parasympathomimetics [cholinergics], initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
